Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study
about
Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysisHormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysisGenetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in womenMetabolic effects of contraceptive steroidsLower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogensThrombophilia and pregnancy: review of the literature and some original data.Criteria for evaluating evidence that laboratory abnormalities are associated with the development of venous thromboembolism.Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study.Laboratory thrombophilias and venous thromboembolism.Risk factors for venous and arterial thrombosisHormonal birth control and pregnancy: a comparative analysis of thromboembolic risk.Estrogens, progestogens and thrombosis.Combined oral contraceptives and the risk of myocardial infarction.Hormones and pregnancy: thromboembolic risks for women.The effects of obesity on venous thromboembolism: A review.Epidemiology and risk factors for venous thrombosis.Combined hormonal contraception and venous thromboembolism.The Yin-Yang of thrombin and activated protein C.Pulmonary absorption of liposomal levonorgestrel.[Venous thromboembolic disease in the region of Sidi Bel Abbes, Algeria: frequency and risk factors].APC resistance: biological basis and acquired influences.Risk factors for heart attack, stroke, and venous thrombosis associated with hormonal contraceptive use.Screening for coagulation disorders in patients with ischemic stroke.A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke.Hormone therapies and venous thromboembolism: where are we now?Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis.Primary prevention of venous thromboembolism.Drug-induced thrombosis: an update.Heparanase procoagulant activity is elevated in women using oral contraceptives.The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women.Third generation oral contraceptives.Sex differences in thrombosis.Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over.Effect of in vitro fertilization treatment and subsequent pregnancy on the protein C pathway.Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.Neutral glycosphingolipid-dependent inactivation of coagulation factor Va by activated protein C and protein S.Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women.Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation.Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate.
P2860
Q24622035-C87B7D13-B69F-4E54-A727-A962D1743F03Q24647720-4536294B-A42E-4AB4-AFB0-E1823570ACA0Q24804326-BC983C3A-BB27-45AC-B951-AA017785B032Q28236638-C722D4C3-4AA5-4822-B507-B913194B59C1Q28607716-D7744329-31ED-4AA5-993B-D33534747E8DQ30665115-02766F48-8434-48B0-AD6C-6362BE856E23Q33954905-550E892C-1084-4818-A41A-8DDDCA09BEBEQ34047313-1CAB78DA-0517-4F7B-8146-C6DFB36C61AAQ34981644-83239E1F-3876-4C05-81FF-D91093FF2692Q34988616-727AEF00-AB40-492C-A06C-78DE050FC237Q35139270-BC998E44-DB9D-4040-B30D-A3025529AE2EQ35181580-A11F6709-47D2-4306-96EA-BAE617654353Q35565498-907BD9FC-B852-46DC-BA53-9D3F696602D3Q35852845-1AB1EF92-9B4B-4A25-9EC2-847A4028DD4FQ35904699-05E9D3D9-DDA7-4084-A162-5A84493C7D55Q36063535-FD547C17-8179-4704-A5AA-AE02F2DF6910Q36845040-C2E16FDE-88D3-404B-BEEC-346BAAE067E2Q37084859-B5BB9950-FC27-4C89-93A9-76FFC9B06748Q37444919-68933A54-4DBF-4D54-8FBB-9422D277B8DFQ37633798-A7AB2DBC-4144-442F-BAEE-35CA8EDAB8A0Q37651037-2A28806C-EBAF-41B0-B50D-1D9EB8D9AA83Q37763371-0943E9D0-6437-4619-AC27-138CD9069D12Q37775992-12931CB8-A72D-4F9C-88C5-D7089B1F9B28Q37790448-F41872F7-FD7E-42C5-97A1-0A0038DFDF79Q37813184-40E18DDB-8662-4915-8E00-CBA8A4AA1429Q37975229-E338C1B1-0E20-4C4B-9E7D-32151CE907CEQ37998002-36856BC0-A69A-4488-B505-D4210F07188AQ38103820-AD7D582B-A72A-4EC1-9ABD-13F3EAC4121BQ39135103-92BF3F75-42B6-4107-8362-6C52CD27B499Q39347912-DA80DDDB-0320-4960-B658-DAC7B095DCF6Q42767540-58C9B1F0-D063-4BD9-8A50-3852C9FCEB0DQ42807454-85849785-3D4A-4213-91C4-0B518778B480Q43665943-F62DEB34-786D-4EA4-A9D4-9BE939B82196Q43795709-ED12B5EE-CCF7-4B71-9473-9A4714705C89Q43795711-A5F7E3F8-CB3A-4BE5-818C-0F8462D7C890Q43821720-EC358E84-5D62-44B7-B1B1-A793D110E8BDQ43910733-24154178-57B8-4C0C-872D-B6A306848D76Q43912236-0ADFCACB-DDCE-45FE-992F-315861FD8414Q44242587-F2215A79-2AEA-43D2-AF68-8D12E8DC9D06Q45154446-D2528024-CE97-46A4-89C1-5EA2FC95E60D
P2860
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Low-dose oral contraceptives a ...... a randomised cross-over study
@ast
Low-dose oral contraceptives a ...... a randomised cross-over study
@en
Low-dose oral contraceptives a ...... a randomised cross-over study
@nl
type
label
Low-dose oral contraceptives a ...... a randomised cross-over study
@ast
Low-dose oral contraceptives a ...... a randomised cross-over study
@en
Low-dose oral contraceptives a ...... a randomised cross-over study
@nl
prefLabel
Low-dose oral contraceptives a ...... a randomised cross-over study
@ast
Low-dose oral contraceptives a ...... a randomised cross-over study
@en
Low-dose oral contraceptives a ...... a randomised cross-over study
@nl
P2093
P1433
P1476
Low-dose oral contraceptives a ...... a randomised cross-over study
@en
P2093
G A Nicolaes
H R Büller
L G Thomassen
M Christella
S Middeldorp
P304
P356
10.1016/S0140-6736(99)06092-4
P407
P50
P577
1999-12-01T00:00:00Z